Posted on: May 17, 2018
W. Shawn Carbonell, MD ’06, PhD ’05, is a founder and CEO of OncoSynergy. The company was founded in 2011 to provide solutions for treatment-resistant cancer through the development of a new class of oncology therapeutics, called Resistance Mechanism Inhibitors (RMIs). RMIs are unique multi-action, tumor-agnostic drug platforms that have shown preclinical promise as monotherapy and in strategic combinations. The lead RMI drug candidate, OS2966, is on track for Phase I clinical trials.
In May 2018, OncoSynergy announced that it has closed a Series A equity round led by Connecticut Innovations (CI) with participation by the current shareholders, including NLabs, Inc., and Korea Information & Communication Co., Ltd. The venture financing will be used to accelerate their lead program, OS2966, to the clinic for the treatment of glioblastoma, the most common and deadliest primary brain tumor in adults. OncoSynergy will be relocating its headquarters from the prestigious JLABS South San Francisco incubator to Connecticut and expanding its team in anticipation of its first clinical trial in 2019.
“As physicians, the founding team of OncoSynergy are absolutely thrilled to be able to bring OS2966 from the lab bench to patients for the first time.” says Carbonell.
Dr. Carbonell received his MD and PhD (Neuroscience) from the University of Virginia NIH-funded Medical Scientist Training Program (MSTP) where he was a Dean’s Merit Scholar. He started neurosurgery residency at Cedars-Sinai Medical Center in 2009. Prior to founding OncoSynergy, he completed two postdoctoral Fellowships in neuro-oncology at the University of Oxford and UCSF.